Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

Style" type="disc">
  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $55.7 million and $41.6 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2010, the Company had cash and cash equivalents of approximately $4.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activity and to complete its plan of operations through December 31, 2010. At the Company's present level of activities, the Company's cash and cash equivalents are believed, at this time, to be sufficient to fund its operations only into the fourth quarter of 2010. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversel
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... , July 27, 2015 According ... Hybridization Market Study (2014-2019) by Type (DNA ISH, RNA ... By End User (Hospitals, Pharma & Biotech Companies, Research ... at $554.4 million 2014 and is estimated to reach ... during the forecast period, 2014 to 2019. ...
    (Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) ... Pharma News Issue" newsletter to their offering. ... burgeoning oncology pipeline and serves as a statement ... in 2015, with a large-scale potentially transformative acquisition ... Key Pharma News covers all major developments in ...
    (Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
    Breaking Medicine Technology:Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
    ... , WALTHAM, Mass., Dec. 14 According ... technology market intelligence, increased use of safety devices for small-bore ... driver of the enteral feeding device markets in both the ... for Enteral Feeding Devices 2010 report finds that the ...
    ... Colo., Dec. 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food and Drug ... suffering from gallstones in whom surgery poses an unacceptable ... Chenodal prescriptions have started to be dispensed to patients ...
    Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
    (Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... The heroin ... country, reported WCNC on July 7th. The rate for heroin usage has ... has gone down considerably, and is a less expensive alternative for those with an ...
    (Date:7/27/2015)... ... July 27, 2015 , ... In a piece ... personal side of plastic surgery and explained why people should not shy away from ... for the excesses of the few and celebrate it for the modern wonder that ...
    (Date:7/27/2015)... Plains, NJ (PRWEB) , ... July 27, 2015 , ... ... tendon of an accomplished athlete. “The patient is high-end athlete, whose accomplishments include ... after 8 months of Achilles tendon pain, which was diagnosed as tendinitis. I ...
    (Date:7/27/2015)... , ... July 27, 2015 , ... ... including emergency notification and mobile collaboration, announced today the ... user interface, language localization and other feature enhancements. , This software release gives ...
    (Date:7/27/2015)... ... July 27, 2015 , ... ... and in-depth research report. The report provides basic information such as calcium ... This report covers the global (US, Europe, Japan etc) industry analysis like ...
    Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
    ... understanding of dopamine release from nerve cells, findings that ... treating Parkinson,s Disease. People with Parkinson,s Disease ... movement and, in extreme cases, a loss of physical ... of dopamine producing nerve cells in the brain. ...
    ... finds increase lowers chance of hospitalization or death ... with heart failure, high doses of the drug losartan, ... admission and death, a new study shows. , Though ... the study focused on whether dose level makes a ...
    ... ... expertise offers a winning combination to companies with large sales forces. , ... Chicago, IL (PRWEB) November 18, ... , knowledge and collaboration platform, and ELA Consulting Group , sales effectiveness and ...
    ... ... of resources to help community health officials make use of the company’s new mapping ... white paper and a free webinar, each demonstrate how Depiction can be used as ... ...
    ... A ... a new technique available at Houston weight loss surgery practice Texas Laparoscopic ... surgical treatment for morbid obesity. , ... (Vocus) November 18, 2009 -- Houston-based Texas Laparoscopic Consultants is a ...
    ... ... families learn five steps for creating joyful holidays and family celebrations. , ... (PRWEB) November 18, 2009 -- PAIRS Foundation is ... joyful holidays and family celebrations. , ,"Holidays can be a time of wonderful celebration, sharing ...
    Cached Medicine News:Health News:Findings that should speed the development of drugs for Parkinson's disease 2Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 2Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4Health News:Five Steps to Happy Family Gatherings at Holiday Time 2
    The Nervous System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the nervous system....
    ... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
    ... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
    Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
    Medicine Products: